What the Research Says
DHEA has a solid evidence base for adrenal insufficiency, where it is considered standard adjunctive therapy. The landmark Arlt et al. (1999) study in the New England Journal of Medicine demonstrated significant quality-of-life improvements in women with adrenal insufficiency taking 50mg daily. For anti-aging applications in healthy older adults, evidence is mixed — some studies show benefits for mood and bone density, while the DHEAge trial showed limited benefits. Intravaginal DHEA (prasterone) received FDA approval in 2016 based on strong RCT evidence for postmenopausal vulvovaginal atrophy.
